drugset / Trial / NCT02168829

Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

NCT02168829

RandomizedParallel-groupOpen-labelPrevention

Summary

This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia. AF is normally associated with an increased risk of stroke which in many patients can be prevented with appropriate blood thinner therapy. This trial will compare a strategy of oral anticoagulant therapy after successful ablation to therapy with an aspirin per day.

Timeline

Start
2016-01
Primary completion
2025-08-14
Completion
2025-08-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule
Comparator Rivaroxaban Other / unclassified 15 mg Oral